Recently, an increasing number of reports have shown the efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) for patients with non-small cell lung cancer (NSCLC) harboring an EGFR mutation with ocular metastasis [4-14]. Here, EGFR is linked to non-small cell lung carcinoma.